Interleukin-13 peptide vaccine induces protective humoral immunity in murine asthma models

Fengbo Wu; Yan Huang; Peng Zhang; Chunting Wang; Yaomei Tian; Lian Lu; Gu He; Li Yang

doi:10.18632/oncotarget.19950

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers: Pathology:

Interleukin-13 peptide vaccine induces protective humoral immunity in murine asthma models

Fengbo Wu, Yan Huang, Peng Zhang, Chunting Wang, Yaomei Tian, Lian Lu, Gu He and Li Yang _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:6678-6690. https://doi.org/10.18632/oncotarget.19950

Metrics: PDF 1405 views | HTML 3048 views | ?

Abstract

Fengbo Wu1, Yan Huang1, Peng Zhang2, Chunting Wang1, Yaomei Tian1, Lian Lu1, Gu He1 and Li Yang1

1 Department of Pharmacy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, P.R. China

2 Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, P.R. China

Correspondence to:

Li Yang, email:

Gu He, email:

Keywords: interleukin-13, asthma, synthetic peptide, vaccine, Pathology Section

Received: June 09, 2017 Accepted: July 25, 2017 Published: August 04, 2017

Abstract

This study presents a rational design approach to discovery synthetic peptide vaccine candidates from endogenous proteins for chronic non-infectious diseases immunological therapeutics. The approach described the screening of key antigenic amino acid residues of the interleukine-13, which is up-regulated expression in asthma, followed by the development of immunological helper epitope peptides via an integrative computational and experimental method. Notably, this totally synthetic peptide vaccine was capable of stimulating humoral immune responses much stronger than those of parental antigenic peptides by enhancing the efficiency of antigen presentation, and had effective treatment in mouse asthma models. Our approach offers new possibilities to discovery therapeutic peptide vaccine candidates for chronic non-infectious diseases, with highly consolidated in silico and animal disease models for fast iterative screening.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19950

Publication Alerts

Research Papers: Pathology:

Interleukin-13 peptide vaccine induces protective humoral immunity in murine asthma models

Abstract